Immunotherapies Stocks List

Related ETFs - A few ETFs which own one or more of the above listed Immunotherapies stocks.

Immunotherapies Stocks Recent News

Date Stock Title
May 15 GMAB Market Chatter: Genmab CEO Says Western Firms Should Tap Into China's 'Impressive Innovation'
May 15 RCUS Arcus Biosciences: A Preview Of Their Outlook Ahead Of ASCO
May 14 SLS SELLAS Life Sciences GAAP EPS of -$0.21
May 14 NBTX NANOBIOTIX Announces US FDA Protocol Acceptance for New Randomized Phase 2 Study Evaluating NBTXR3 for Patients with Stage Three Lung Cancer
May 14 SLS SELLAS Life Sciences Reports First Quarter 2024 Financial Results and Provides Corporate Update
May 14 GMAB Genmab to Present New and Updated Results From Multiple Clinical Trials Evaluating Epcoritamab Across Various B-Cell Malignancies at the 2024 European Hematology Association (EHA) Congress
May 14 IMTX Immatics reports Q1 results
May 14 IMTX Immatics Announces First Quarter 2024 Financial Results and Business Update
May 14 GMAB Danish biotech says companies should tap into China’s ‘impressive innovation’
May 12 RCUS Arcus Biosciences, Inc. (NYSE:RCUS) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates
May 10 EVAX Evaxion receives Nasdaq notification over minimum stockholders’ equity requirement
May 10 EVAX Evaxion Receives Nasdaq Notification
May 10 RCUS Arcus Biosciences Surpasses Analyst Revenue Forecasts in Q1 2024
May 10 ALPN Alpine Immune Sciences Inc (ALPN) Reports Q1 2024 Financials Amid Pending Acquisition by Vertex ...
May 10 ALPN Alpine Immune ticks higher as HSR waiting period for Vertex Pharma deal expires
May 10 RCUS Arcus Biosciences First Quarter 2024 Earnings: Beats Expectations
May 9 ALPN Alpine Immune Sciences GAAP EPS of -$0.28 beats by $0.12, revenue of $7.03M beats by $3.51M
May 9 ALPN Alpine Immune Sciences Reports First Quarter 2024 Financial Results
May 9 RCUS Arcus Biosciences, Inc. (NYSE:RCUS) Q1 2024 Earnings Call Transcript
May 9 RCUS Arcus Biosciences Inc (RCUS) Q1 2024 Earnings Call Transcript Highlights: Strategic ...
Immunotherapies

Immunotherapy is the treatment of disease by activating or suppressing the immune system. Immunotherapies designed to elicit or amplify an immune response are classified as activation immunotherapies, while immunotherapies that reduce or suppress are classified as suppression immunotherapies.

In recent years, immunotherapy has become of great interest to researchers, clinicians and pharmaceutical companies, particularly in its promise to treat various forms of cancer.Immunomodulatory regimens often have fewer side effects than existing drugs, including less potential for creating resistance when treating microbial disease.Cell-based immunotherapies are effective for some cancers. Immune effector cells such as lymphocytes, macrophages, dendritic cells, natural killer cells (NK Cell), cytotoxic T lymphocytes (CTL), etc., work together to defend the body against cancer by targeting abnormal antigens expressed on the surface of tumor cells.
Therapies such as granulocyte colony-stimulating factor (G-CSF), interferons, imiquimod and cellular membrane fractions from bacteria are licensed for medical use. Others including IL-2, IL-7, IL-12, various chemokines, synthetic cytosine phosphate-guanosine (CpG) oligodeoxynucleotides and glucans are involved in clinical and preclinical studies.

Browse All Tags